Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Constitutive activation of cKIT kinase mediated signaling pathway is essential for the tumorigenesis of GISTs. 1,2 cKIT kinase is a type III receptor tyrosine kinase that upon stem cell factor (SCF) stimulation will activate downstream signaling pathways such as RAS/RAF/ ERK and PI3K/AKT to regulate the cell proliferation, survival, apoptosis, and differentiation. Approximately 75% GISTs harbor oncogenic gain-of-function KIT gene mutations that mimic the SCF-induced constitutive signaling pathway activation. 3 Currently, over 20 different functional mutations have been identified in the clinic. 4 Most primary mutations such as L576P and V559D/A/G mutants occur in the extracellular domain and juxtamembrane (JM) domain. [5] [6] [7] Secondary mutations are induced by drug treatment and usually located at the ATP binding pocket such as cKIT V654A and the gatekeeper mutant T670I, or at the activation loop such as D816V/H, N822K, and A829P . [8] [9] [10] Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors Introduction of imatinib as the first-line therapy has remarkably improved the survival of the GISTs patients, however most patients eventually experience disease progression as the development of secondary mutations in the cKIT ATP binding pocket and activation loop upon treatment. 11, 12 Sunitinib, which is approved as secondline therapy for imatinib-refractory GIST, could overcome secondary mutants in the ATP binding pocket such as V654A and gatekeeper mutant T670I, but it was insensitive to most of the mutants in the activation loop. [13] [14] [15] Even regorafenib, which is the third-line treatment approved for imatinib-and sunitinib-resistant and intolerant GISTs, was only moderately sensitive against those secondary mutations. 16 In addition, the short median progression-free survival (PFS) of sunitinib and regorafenib (6.8 months for sunitinib and 4.8 months for regorafenib) has also limited their clinical applications. [15] [16] [17] Ponatinib and pazopatinib are currently undergoing clinical investigation for GISTs and have also been demonstrated to be potent against a variety of imatinib-resistant mutants. However, safety concerns, such as high risk of arterial occlusive events for ponatinib and hypertension for pazopatinib, might also restrict their clinical application. 18, 19 Hence, there is still an urgent need to develop more targeted therapies that bear different mutant sensitivity spectra and safety profiles for GISTs.
Based on high-throughput screening of the library of US Food and Drug Administration (FDA) approved drugs, we found that axitinib, a vascular endothelial growth factor receptor (VEGFR) kinase inhibitor that has been approved for the renal cell carcinoma (RCC), was sensitive to a variety of cKIT primary and secondary mutants and displayed a different mutant sensitivity spectrum compared with the clinical drugs for GISTs, including imatinib, sunitinib, and regorafenib. In this report, we describe the detailed preclinical evaluation of axitinib activity in in vitro and in vivo GISTs models bearing primary and secondary cKIT mutants.
Materials and methods

Inhibitors
Imatinib, sunitinib, regorafenib, and axitinib were purchased from a commercial chemical vendor (Haoyuan Chemexpress Inc.) and dissolved in 100% dimethyl sulfoxide (DMSO).
c KIT protein purification
The sequences encoding wild-type cKIT and T670I cKIT residues 544-935 with a Histag were cloned into baculovirus expression vector pFASTHTA. The proteins were expressed by infecting SF9 cells with high-titer viral stocks for 48 h. Cells were harvested and lysed in 25 mM Tris pH 7.4, 250 mM NaCl, and 1 mM PMSF. The supernatant was loaded to Ni-NTA Column (QIAGEN, 1018244). Then the proteins were step eluted with the same buffer with 250 mM imidazole. The eluted proteins were loaded on a Superdex-200 column equilibrated in 25 mM Tris (pH 7.4), 250 mM NaCl, 1 mM DTT, and 1 mM EDTA. Peak fractions were concentrated to 2 mg/ml and flash frozen.
Kinase biochemical assay
The ADP-Glo™ kinase assay (Promega, Madison, WI) was used to screen axitinib for its cKIT and the relevant mutation inhibition effects. The kinase reaction system contains 9 μl cKIT (12.5 ng/μl) or cKIT T670I (20 ng/μl), 1 μl of serially diluted axitinib, and 10 μl substrate Poly (4:1 Glu, Tyr) peptide (0.4 μg/μl) (Promega, Madison, WI) with 100 μM ATP (Promega, Madison, WI). The reaction in each tube was started immediately by adding ATP and kept going for an hour at 37°C. After the tube cooled for 5 min at room temperature, 5 μl solvent reactions were carried out in a 384-well plate. Then 5 μl of ADP-Glo™ reagent was added into each well to stop the reaction and consume the remaining ATP within 40 min. At the end, 10 μl of kinase detection reagent was added into the well and incubated for 30 min to produce a luminescence signal. The luminescence signal was measured with an automated plate reader (Envision, PE, USA) and the doseresponse curve was fitted using Prism 5.0 (GraphPad Software Inc., San Diego, CA). The biochemical tests of other targets were provided by Invitrogen (Carlsbad, CA, USA).
Molecular modeling
All calculations were performed using the Schrödinger Suite. The DFG-out KIT complex (PDB ID: 3G0E for axitinib and 1T46 for imatinib, respectively) was used for docking studies. The crystal structure were prepared using the Protein Preparation Wizard and the T670I/ V654A mutant were modeled in situ within Maestro. The ligand structures were built in Maestro and prepared for docking using LigPrep Colony formation assay GIST-T1, GIST-882, GIST-48B, and GIST-5R cells were trypsinized and dispensed into individual wells of six-well tissue culture dishes with a density of 50,000 cells per well. Cells were maintained in a humidified 5% CO 2 incubator at 37°C for 15 days, and continuously treated with serially diluted axitinib, imatinib, sunitinib, and regorafenib. On the 15th day, the numbers of colonies in each well were quantified and each measurement was performed in triplicate. The data were normalized to vehicle treatment and quantification was analyzed by Image J software (National Institutes of Health, USA).
Signaling pathway examination GIST-T1, GIST-882, GIST-5R, and GIST-48B cells were treated with DMSO, serially diluted axitinib, 1 μM imatinib, and 1 μM sunitinib for 1 h. Cells were then washed with cold PBS and lysed in RIPA buffer (Beyotime, China) with a protease inhibitor cocktail (Roche). Immunoblotting was performed by standard protocols. The following antibodies were used at a range of antibody concentrations as indicated by the manufacturers to probe for specific proteins: phosphorylated KIT (Tyr719), KIT (Tyr703), AKT (Ser473), AKT (Thr308), STAT3 (Ser705), STAT5 (Tyr694), ERK1/2 (Thr202/Tyr204), and p70 S6K (Thr 389) were all from Cell Signaling Technology. Rabbit polyclonal antibody to phosphorylated KIT (Tyr823) was from Invitrogen. β-actin antibody was purchased from Sigma.
Cell cycle analysis GIST-T1, GIST-882, GIST-5R, and GIST-48B cells were treated with DMSO, serially diluted axitinib (0.3, 1, and 3 μM), 1 μM imatinib, and 1 μM sunitinib for the indicated periods. The cells were fixed in 70% cold ethanol and incubated at −20°C overnight then stained with PI/RNase staining buffer (BD Pharmingen). Flow cytometry was performed using a FACS Calibur (BD), and results were analyzed by ModFit software.
Apoptosis effect examination
GIST-T1, GIST-882, GIST-5R, and GIST-48B cells were treated with DMSO, serially diluted axitinib, 1 μM imatinib, and 0.1 μM sunitinib for the indicated periods. Cells were collected and analyzed by Western blotting using the following antibodies: PARP and caspase-3 from Cell Signaling Technology. β-actin antibody was purchased from Sigma.
GIST-T1, GIST-5R xenograft, and Ba/F3 cKIT-V654A allograft tumor models
Four-week old female BALB/c-nu/nu mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing City, Jiangsu Province, China Hospital (approval number 2018A026). The written informed consent was obtained from all patients who take part in the study. The protocol was carried out in accordance with Good Clinical Practice standards and the Declaration of Helsinki. Briefly, patient resections were placed in a sterile conical tube containing DMEM media (Invitrogen) with 5% antibiotic-antimycotic (Fisher Scientific) on wet ice during transport from the operating room to the research laboratory. Fragments of freshly obtained tumor tissues were dissociated using collagenase/hyaluronidase and dispase (StemCell Technologies) at 37°C for 2 h with shaking in 37°C as described previously. 22 Primary cells were then placed in flasks coated with collagen I (Corning) in culture medium. The culture medium included DMEM/F12 medium with freshly added supplements: 5% FBS (Gibco), primocin (Invivogen), Glutamax-I (Gibco), 25 μg/ ml hydrocortisone (Sigma), 125 ng/ml EGF (Sigma), 5 μg/ml insulin (Gibco), and 10 μM Rho kinase inhibitor Y27632 (Haoyuan Chemexpress Inc.) in humidified 37°C/5% CO 2 incubators at 2% O 2 . Medium was replaced every 3 days and the primary cells were cultured for a period of 3-4 weeks.
All the experiments were conducted using low-passage primary cultures. 
Statistical analyses
All statistical analyses were performed using Graph Pad Prism software (GraphPad Software Inc., La Jolla, CA, USA). Three independent replicates were performed for each experiment. Data are presented as mean ± standard deviation (SD), with n indicating the number of replicates. Differences between groups were assessed by a paired t test and accepted as significant at p < 0.05.
Results
In vitro inhibitory activity of axitinib against a panel of cKIT kinase primary and secondary mutants
We first examined axitinib on a panel of cKIT kinase primary and secondary mutants transformed Ba/F3 cells by comparing with imatinib, sunitinib, and regorafenib [ Figure 1 (a) and Supplemental Table 1 ]. The results demonstrated that axitinib was active to cKIT wild type (GI 50 : 50 nM). For the JM domain primary mutants such as L576P and V559D/A/G, axitinib displayed better potencies than imatinib, sunitinib, and regorafenib. Like sunitinib and regorafenib, axitinib could also inhibit the imatinib-resistant gatekeeper mutant T670I (GI 50 : 108 nM) and JM domain/ATP binding pocket combined mutants T670I/V559D (GI 50 : 191 nM), although it was less potent than sunitinib. Interestingly, axitinib showed similar potencies to sunitinib against another imatinib resistant mutant V654A in ATP binding pocket (GI 50 : 5 nM) and combined mutants V654A/V559D (GI 50 : 20 nM), and the efficacy is better than regorafenib. In addition, axitinib performed better than imatinib, sunitinib, and regorafenib on the secondary mutants A829P in the activation loop. These results suggested that cKIT wild type, JM domain primary mutants L576P and V559D/A/G, imatinib-resistant mutants V654A in the ATP binding pocket are sensitive to axitinib and the mutant in the activation loop A829P was also sensitive to axitinib, compared with imatinib, sunitinib, and regorafenib.
Given the fact that all of these inhibitors are multiple-target compounds and in order to confirm the on-target effects on those transformed Ba/F3 cells, we then assessed KIT Y703, Y719, and Y823 phosphorylation in axitinib-treated Ba/F3 cells [ Figure 1 (b) and Supplemental Figure 1] . The results showed that axitinib could potently inhibit the most common cKIT phosphorylation site Y703 2 of the cKIT wild type, primary mutants L576P and V559D/A/G within the JM domain, secondary mutants V654A and V654A/V559D within the ATP binding pocket, as well as secondary mutant A829P within the activation loop. It was less potent versus the drug-resistant secondary mutant T670I and T670I/V559D within the ATP binding pocket. Not surprisingly, it had lower potency against the activation loop mutants such as D816H and lowest potency against the D816V mutant. The EC 50 s correlate with the GI 50 s of axitinib in these cells [ Figure 1(c) ]. In addition, we also examined the inhibitory activity of axitinib against purified cKIT wild type and mutant proteins in the biochemical enzymatic assay with Invitrogen's SelectScreen technology [ Figure 1( 
Structural basis of the sensitivity of axitinib against cKIT-V654A and T670I mutants
In order to better understand the structural basis of the sensitivity of axitinib, we then docked it by the relatively larger residue Val. Therefore, the mutation resulted in activity loss, although it was not as significant as T670I mutant [ Figure 2 (f)]. 23 In vitro activity of axitinib in GISTs cell lines harboring primary and secondary mutants We next examined the antiproliferative effect of axitinib against a panel of established GIST cancer cell lines [ Figure 3(a) ]. As expected, among four drugs we tested, axitinib was the most potent to GIST-T1 (GI 50 : 21 nM), which harbors a primary mutation in the JM domain (∆560-578). It also displayed similar potency to imatinib and sunitinib against GIST-882, which harbors K642E mutant in the c-Helix of the ATP binding pocket but was more potent than regorafenib. In addition, axitinib was more sensitive than regorafenib to the imatinib resistant GIST-5R cells, which carry an additional missense mutation encoding KIT T670I (exon 14), but less sensitive than sunitinib. For GIST-48B, a cKIT-independent cell line, none of them exhibited good activity. These growth inhibition efficacies also correlated well with the results in colony formation assays [ Figure 3(b) ].
In order to further confirm the on-target effect of axitinib on these cell lines, we next determined the signaling pathway response upon treatment [ Figure  4 (a)]. In the GIST-T1 and GIST-882 cells, it could potently inhibit phospho-cKIT Y719, Y703, and Y823 and the downstream signaling mediators including phospho-AKT, phospho-S6K, phospho-S6, phospho-ERK, phospho-STAT3, and phospho-STAT5. Interestingly, in the cKIT T670I cell line GIST-5R, neither axitinib nor sunitinib displayed great inhibitory effect against phosphocKIT Y719, but both of them still potently inhibited phospho-cKIT Y703, Y823, and downstream phospho-AKT, ERK, S6K, S6, STAT3, and STAT5. In the KIT-independent cell line GIST48B, no detectable levels of phosphorylated KIT and minimal levels of total KIT were found. The downstream mediators of cKIT signalling pathway were not affected obviously after axitinib treatment.
Axitinib induced the cell cycle arrest and apoptosis in GISTs cell lines
We then examined the effects of axitinib on cell cycle progression and apoptosis. Not surprisingly, axitinib blocked cell cycle progression at G0/G1 phase at 0.3 μM in the drug-sensitive cell lines including GIST-T1, GIST-882, and GIST-5R, but not in the insensitive cell line GIST-48B. While starting from 1 μM, the cell cycle was arrested at G2/M phase in all of the cell lines we tested [ Figure  4(b) ]. This may due to the aurora kinase activity of axitinib (K d of aurora A:B:C = 72, 11, and 1.3 nM respectively). 24, 25 To confirm that, we performed immunofluorescence examination (Supplemental Figure 2) . The results were supportive of the cell cycle data, with the centrosome separation and spindle assembly being interrupted by axitinib treatment. Axitinib also induced apoptosis in KIT mutant GIST cell lines in a dose-dependent manner, but not in GIST-48B by examining cleaved PARP and caspase-3 [ Figure 4 (c)]. These results were in accordance with the growth inhibition effects observed in those GIST cell lines.
Axitinib suppressed the tumor growth of GIST-T1, GIST-5R, and cKIT-V654A Ba/F3 cells mediated mouse model
To further investigate the potential of the clinical application of axitinib, we then examined its in vivo efficacies in several different preclinical models. In the GIST-T1 and GIST-5R cells inoculated xenograft mouse models and the cKIT-V654A Ba/F3 inoculated allograft mouse model, oral administration of axitinib at different dosages (25, 50 , and 100 mg/kg/day) did not show any apparent toxicity (Supplemental Figure  3) . In the GIST-T1 xenograft mouse model, axitinib exhibited dose-dependent tumor growth suppression and the TGI (tumor inhibition rate) was 53% at 100 mg/kg/day dosage [ Figure 5(a) ].
In the GIST-5R xenograft mouse model, 100 mg/ kg/day dosage of axitinib could almost completely block the tumor progression and showed a TGI of 88%, whereas the same dosage of imatinib showed limited effect on tumor growth [ Figure  5 (b)]. As expected, reduced phosphorylation of cKIT and related downstream mediators such as STAT3, AKT, and ERK in tumors were observed compared with the vehicle-treated controls (Supplemental Figure 4) . Furthermore, we found that at 100 mg/kg dosage, aurora kinase started to be inhibited, which might help to enhance the antitumor efficacy of axitinib in vivo (Supplemental Figure 4) . These data were also consistent with the results we observed in the cell cycle arrest assays and centrosome separation experiments [ Figure 4 (b) and Supplemental Figure 2 ]. In the cKIT-V654A Ba/F3 inoculated allograft mouse model, axitinib also showed a dose-dependent tumor growth inhibition. Even at 25 mg/kg/day dosage, the TGI achieved was 66.8%, whereas journals.sagepub.com/home/tam 9 imatinib did not show significant inhibition on tumor growth [ Figure 5 (c)]. Immunohistochemical (IHC) staining results showed that axitinib dose-dependently inhibited proliferation (Ki-67 stain) and induced apoptosis (TUNEL stain) in all three mouse models (Supplemental Figure 5) . 
Axitinib is effective in human GIST patientderived primary cells
We next tested the effects of axitinib in a more physiological setting in an ex vivo culture of human GIST patient-derived primary cells (Supplemental Table 2 ). We observed that ex vivo culturing of patient A's primary cells for 6 days in the presence of axitinib (1 μM) substantially decreased both the cKIT-positive and CD34-positive GIST patient-derived primary cells [ Figure 6 (a)]. These results were confirmed using another GIST IHC marker DOG1 [Figure In order to further quantify these effects, we next tested the antiproliferation effect of axitinib on the other three GIST patients. Patients B and C harbored cKIT-V559D and cKIT-K642E mutation, respectively, and were evaluated by whole-transcriptome sequencing, whereas there is no cKIT mutation in patient D's primary cells (Supplemental Table 3 ). The results demonstrated that the viability of these primary cells was inhibited by axitinib dosedependently in all three patient samples [ Figure  6 (c)], consistent with our previous data in GIST cell line models. Interestingly, patient D, harboring cKIT wild type, responded to axitinib whereas imatinib and sunitinib did not display potent inhibition even at 3 μM concentration. We speculated that aurora kinase inhibition might contribute to this efficacy because starting from 1 μM concentration axitinib could induce G2/M arrest and centrosome separation interruption, which was different from other cKIT kinase inhibitors [ Figure 4 (b) and Supplemental Figure 2 ]. To confirm this result, we also examined the signaling pathway in the primary cells from patient D. The results showed that both the phospho-cKIT and phospho-Histone H3, which is the downstream substrate of aurora kinase and a widely used marker for aurora kinase inhibition efficacy, [26] [27] [28] were potently inhibited by axitinib at 1 μM (Supplemental Figure 6 ). These results revealed that at higher concentration, the aurora kinase inhibition would also contribute to the antiproliferation effect of axitinib.
Discussion
With the development of the next-generation sequencing, more and more primary gain-of-function mutations and drug-resistant mutations are being identified from patients in the clinic. For instance, more than a dozen different cKIT mutations have already been found in GIST patients. 29 Although there have been three different targeted drugs approved for GISTs, in the precision medicine era that each specific mutant may require a specific corresponding treatment to achieve optimal clinic response for the individual patient, there remains a clear need for more agents that display different target-sensitive spectra to overcome or suppress the different resistance mutations of cKIT that have emerged in GIST patients.
In this study, through applying drug repurposing strategies, we have identified axitinib, which has been approved for the clinical use in RCC, is sensitive against a panel of primary gain-of-function cKIT mutants and secondary drug-resistant mutants. Meanwhile, it exhibited a different drug sensitivity spectrum compared with sunitinib and regorafenib. We assessed the effects of axitinib in 13 engineered Ba/F3 cell lines, 4 GIST cell lines, and 4 GIST patient-derived primary cell models, with consistent results observed across these different model systems. We also analyzed the binding mode of the KIT kinase and axitinib, with comparisons with the KIT/imatinib structure to provide a structural basis of the KIT inhibitory profile of axitinib. As axitinib has been clinically used and the concentration in human (5-10 mg b.i.d. dosage would provide a C max around 250 nM concentration 30 ) could cover the IC 50 range of axitinib against most cKIT primary mutants and imatinib-resistant mutants including T670I and V654A, we envisioned that it might have the potential for application in the clinic.
In the GIST patient-derived primary cells with wild-type c-KIT (lacking cKIT mutation), imatinib and sunitinib were not sensitive to these primary patient cells, which was also reported in the clinic. [31] [32] [33] Interestingly, we found axitinib displayed drug response in these wild-type c-KIT GIST primary cells. After examined the signaling pathway in patient D, we found that both phospho-cKIT and the downstream marker of aurora kinase, phospho-HH3(S10), were inhibited after axitinib treatment. Therefore, we speculate that at relatively lower concentrations (concentration less than 1 μM, which could cover the IC 50 ranges of the axitinib against most cKIT mutants), axitinib mainly exerts its efficacy through the cKIT inhibition, whereas at higher concentrations, aurora kinase inhibition might help to enhance the antiproliferative effect of axitinib. Hence, our finding further suggested that axitinib with different drug sensitivity profiles from current treatments of GIST could provide a new option for the clinic.
However, like sunitinib and regorafenib, axitinib still lacks high potency against the imatinib-resistant mutants occurring in the cKIT activation loop. As it is difficult to predict the conformational change of the activation loop mutations, which makes the rational design of new inhibitors very challenging, drug repurposing strategies might still be a feasible approach to find drugs to overcome these mutations.
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